Etanercept injection: new hope for rheumatoid arthritis and ankylosing spondylitis

Etanercept injection (trade name: Enbrel®) is a biological agent. Since its introduction, it has brought new treatment hope to patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).

For patients with moderately to severely active rheumatoid arthritis, when traditional disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, are ineffective, etanercept injection has become an important treatment option. By inhibiting the activity of tumor necrosis factor (TNF), it effectively reduces joint inflammation, relieves patients' symptoms such as pain, swelling and morning stiffness, and improves their quality of life. Clinical trials have shown that etanercept injection can significantly reduce the progression rate of joint damage shown by X line detection and protect joint function.

Ankylosing spondylitis is a chronic inflammatory disease that mainly affects the sacroiliac joints, spinal apophyses, paraspinal soft tissues and peripheral joints. Etanercept injection also inhibits the activity of TNF and reduces the damage caused by inflammatory reactions to joints and spinal tissues, thereby relieving patients' symptoms such as low back pain, morning stiffness, and joint swelling. For patients with severely active ankylosing spondylitis, etanercept injection provides a new treatment approach when conventional treatments are ineffective.

The safety of etanercept injection is relatively good. Although some adverse reactions may occur during use, such as injection site reactions (pain, swelling, etc.), infections (upper respiratory tract infection, skin infection, etc.), most patients can tolerate it. Compared with traditional anti-rheumatic drugs, etanercept injection has relatively few side effects and has less impact on the functions of important organs such as liver and kidney function.

The use of etanercept injection needs to be under the guidance of a doctor, who will develop a personalized treatment plan based on the patient's specific situation. The recommended administration method is subcutaneous injection, and the dosage and frequency may vary depending on the patient's condition and individual differences. During the treatment process, doctors will regularly monitor the patient's condition changes and adverse reactions, and adjust the treatment plan in a timely manner.

Reference materials:https://www.drugs.com/etanercept.html

xa0